BioCentury
ARTICLE | Clinical News

Conatus down on Phase IIb NASH miss

December 6, 2018 8:01 PM UTC

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) lost $2.56 (57%) to $1.94 on Thursday after it said all three doses of emricasan missed the primary endpoint of improving mean hepatic venous pressure gradient (HVPG) from baseline to week 24 vs. placebo in the Phase IIb ENCORE-PH trial to treat non-alcoholic steatohepatitis.

The double-blind, international trial enrolled 263 patients with compensated or early decompensated liver cirrhosis and severe portal hypertension to receive placebo or twice-daily 5, 25 or 50 mg oral emricasan for 24 weeks. Data from a six-month extension of ENCORE-PH are expected in mid-2019...

BCIQ Target Profiles

Caspases